ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0138

SARS-CoV-2 Vaccine Acceptance, Hesitancy and Uptake in a Cohort of Patients with Inflammatory Rheumatic Diseases (IRD)

iulia roman1, Xenofon Baraliakos2, Uta Kiltz3, Juergen Braun4 and Ioana Andreica5, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, 4Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, 5Rheumazentrum Ruhrgebiet Herne, Herne, Germany

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, COVID-19, Health Care, Infection, prevention

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Epidemiology & Public Health Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Vaccine acceptance is important to achieve high vaccination coverage and possibly herd immunity. Related to the evolution of the SARS-CoV-2 pandemic with its socio-political implications and efforts to mitigate it, public acceptance of the vaccine may have changed over time and have influenced vaccine uptake.The aim of this study was to examine the extent to which the initial acceptance or hesitancy to vaccinate against SARS-CoV-2 have changed over time, whether this has influenced vaccine uptake, and to identify predictive factors for vaccine hesitancy. In addition, we compared vaccine uptake of IRD patients with data from the general population in Germany.

Methods: Sociodemographic and disease-specific data and comorbidities of patients with IRD presenting to our tertiary center between February-April 2021 were assessed and patients were asked to complete a structured questionnaire on SARS-CoV-2 vaccination including a question on their acceptance of vaccination against SARS-CoV- 2 on a numerical rating scale (NRS) from 0 to 10. We defined patients as being hesitant if their score was < 5. Information on SARS-CoV-2 vaccination was collected from their medical records between January and December 2021. Information on the general population in Germany was collected from COVIMO (COVID-19 Vaccination Rate Monitoring in Germany) reports. Binomial logistic regression was used to identify predictors of hesitancy and chi-square tests to assess differences between groups.

Results: Complete vaccination data of 423 out of 514 patients initially enrolled in the study (82.2%) were available. The majority of patients (n=383) agreed to receive SARS-CoV-2 vaccination (90.5%), while only 33 had been hesitant (7.8%). A total of 379 initially acceptive patients were at least once vaccinated (98.9%). On the other hand, 29 of the initially hesitant patients (87.8%) received at least one vaccination (Fig.1).
Regarding the temporal distribution of vaccine uptake there was no significant difference between patients who had initially been hesitant and those who had initially accepted and then ultimately underwent vaccination. Both groups had an approximately 50% uptake until July 2021: 48.2% vs 66.2% (p=0.18). A logistic regression model to identify predictors of vaccination hesitancy showed that out of all variables analysed, only female sex, age below 60 years and being a vaccine opponent significantly predicted hesitancy (p=0.005). According to COVIMO reports between February-April 2021, 79.5% of the general adult population in Germany agreed to be vaccinated, while 20.5% were hesitant. Furthermore, the vaccination rate of patients receiving 2 vaccinations in December 2021 (Table1) was higher in IRD patients (88.8%) than in the general German population (85.4%).

Conclusion: In this study, we observed a high vaccination uptake rate in IRD patients – even a higher than expected from the reported vaccination acceptance rate and potentially a bit higher than in the general population. Indeed, most IRD patients had received the basic vaccination on time. The vaccination campaigns and educational activities performed may have been successful. In this regard, more attention should be paid to young patients and females.

Supporting image 1

Table 1: Demographics/disease characteristics and predictive variables of vaccination hesitancy

Supporting image 2

Figure 1: Change from previous COVID_19 vaccination intention to vaccination uptake in the IRD cohort


Disclosures: i. roman: None; X. Baraliakos: AbbVie, 2, 6, 12, Paid instructor, BMS, 2, 6, 12, Paid instructor, Chugai, 2, 6, 12, Paid instructor, Eli Lilly, 2, 6, 12, Paid instructor, Galapagos, 2, 6, 12, Paid instructor, Gilead, 2, MSD, 6, 12, Paid instructor, Novartis, 2, 5, 6, 12, Paid instructor, Pfizer, 2, 6, 12, Paid instructor, UCB Pharma, 2, 5, 6, 12, Paid instructor; U. Kiltz: AbbVie, 2, 5, 6, Amgen, 5, Biocad, 2, 6, Biogen, 5, Chugai, 2, 6, Eli Lilly, 2, 6, Fresenius, 5, 6, Grünenthal, 2, 6, GSK, 5, Hexal, 5, Janssen, 2, 6, MSD, 2, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 6, UCB, 2, 6; J. Braun: AbbVie/Abbott, 2, 5, 6, Amgen, 2, 5, 6, Boehringer-Ingelheim, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 5, 6, Celgene, 2, 5, 6, Celltrion, 2, 5, 6, Centocor, 2, 5, 6, Chugai, 2, 5, 6, Eli Lilly, 2, 5, 6, Medac, 2, 5, 6, MSD (Schering-Plough), 2, 5, 6, Mundipharma, 2, 5, Novartis, 2, 5, 6, Pfizer (Wyeth), 2, 5, 6, Roche, 2, 5, 6, Sanofi-Aventis, 2, 5, 6, UCB, 2, 5, 6; I. Andreica: None.

To cite this abstract in AMA style:

roman i, Baraliakos X, Kiltz U, Braun J, Andreica I. SARS-CoV-2 Vaccine Acceptance, Hesitancy and Uptake in a Cohort of Patients with Inflammatory Rheumatic Diseases (IRD) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/sars-cov-2-vaccine-acceptance-hesitancy-and-uptake-in-a-cohort-of-patients-with-inflammatory-rheumatic-diseases-ird/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sars-cov-2-vaccine-acceptance-hesitancy-and-uptake-in-a-cohort-of-patients-with-inflammatory-rheumatic-diseases-ird/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology